Chemically Modified Curcumin for Promoting Resolution of Inflammation

Stony Brook University Background
It has long been known (especially in Asian countries, e.g., India, China) that the natural spice curcumin, an active ingredient of turmeric, has broad health benefits. More recently, Stony Brook University inventors have synthesized and tested the safety and efficacy of a series of novel chemically-modified curcumins (CMCs) which have shown significantly enhanced efficacy in a variety of inflammatory diseases.
Technology Overview
Chemically Modified Curcumin (CMC-2.24) is a pre-clinical drug candidate being developed as an FDA-approved, once-daily, orally-administered prescription medication for the treatment of patients with inflammatory disease. CMC-2.24 is a proprietary, chemically-modified, phenylamino carbonyl analog of curcumin. The zinc-binding capabilities of this novel tri-ketonic molecule make it superior to the di-ketonic natural curcumin as an MMP inhibitor, while removal of the -OCH3 groups has rendered the compound more soluble with improved pharmacokinetics.

Directly inhibits the proteolytic activity and expression of several pathological MMPs (MMP=-2, MMP-9,MMP-12)
Normalizes impaired polymorphonuclear leukocytes and macrophage function, and prevents Excessive macrophage accumulation in exudates
Inhibits the conversion of pro-MMPs to active-MMP forms
Normalizes the production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)
Increases levels of pro-resolution mediators (IL-10, lipoxin A4).


Crohn’s Disease


Development Partner

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More